Hypertension
Conditions
Interventions
DRUG: Orforglipron(Other Name: LY3502970)
Administered orally.
DRUG: Placebo
Administered orally.
(Study Arms)
Experimental: Orforglipron (GZL1)
Participants will receive orforglipron orally or
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Has systolic blood pressure (SBP) >= 140 mmHg and/or diastolic blood pressure (DBP) >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at screening (Visit 1). - Has SBP >= 140 mmHg and/or DBP >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at week 0 (Visit 3). - Untreated for hypertension, or on stable antihypertensive medications >= 30 days prior to Visit 1. - Have a body mass index (BMI) >= 25 kg/m2.
Exclusion criteria
Exclusion criteria: - Has SBP >=170 mmHg and/or DBP >=110 mmHg at Visit 1 or at Visit 3. - Has known secondary causes of hypertension - Have heart failure with reduced ejection fraction (HFrEF) diagnosis - Have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). - Have type 1 diabetes (T1D) - Have acute or chronic hepatitis, including a history of autoimmune hepatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Allocated to Each ISA [ Time Frame: Week -8 to Week 0 | — |
Countries
Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed